
Please try another search
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Name | Age | Since | Title |
---|---|---|---|
Bruno Francois | - | 2024 | Clinical Advisor |
Mitchell M. Levy | - | - | Clinical Advisor |
Clifford S. Deutschman | - | - | Clinical Advisor |
Gili Hart | 50 | 2014 | Independent Director |
Shai Novik | 59 | 2014 | Executive Chairman |
Abraham Havron | 77 | 2014 | Independent Director |
Roger James Pomerantz | 68 | 2022 | Independent Vice Chairman of the Board |
Andrew E. Singer | 54 | 2023 | Independent Director |
Tobias Winkler | - | 2024 | Clinical Advisor |
Mervyn Singer | - | 2024 | Clinical Advisor |
Ali Mobasheri | - | 2024 | Clinical Advisor |
David Hunter | - | 2024 | Clinical Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review